Concentration-Dependent Activity of Hydromethylthionine on Cognitive Decline and Brain Atrophy in Mild to Moderate Alzheimer’s Disease

BACKGROUND: Although hydromethylthionine is a potent tau aggregation inhibitor, no difference was found in either of two Phase III trials in mild to moderate Alzheimer’s disease (AD) comparing doses in the range 150–250 mg/day with 8 mg/day intended as a control. OBJECTIVE: To determine how drug exp...

Descripción completa

Detalles Bibliográficos
Autores principales: Schelter, Bjoern O., Shiells, Helen, Baddeley, Thomas C., Rubino, Christopher M., Ganesan, Harish, Hammel, Jeffrey, Vuksanovic, Vesna, Staff, Roger T., Murray, Alison D., Bracoud, Luc, Riedel, Gernot, Gauthier, Serge, Jia, Jianping, Bentham, Peter, Kook, Karin, Storey, John M.D., Harrington, Charles R., Wischik, Claude M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6918900/
https://www.ncbi.nlm.nih.gov/pubmed/31658058
http://dx.doi.org/10.3233/JAD-190772

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6918900/
https://www.ncbi.nlm.nih.gov/pubmed/31658058
http://dx.doi.org/10.3233/JAD-190772

Ejemplares similares